| Literature DB >> 32634861 |
J-F Yang1, X-F Xiong1, Y Xiao1, L Wei1, L Li1, M Yang1, Y-C Han1, H Zhao1, C-R Li1, N Jiang1, S Xiong1, L-F Zeng1, Z-G Zhou2, S-P Liu2, N-S Wang3, Y Fan3, L Sun1.
Abstract
AIMS: To examine the association between 24 literature-based single nucleotide polymorphisms and diabetic kidney disease in Chinese people with type 2 diabetes. METHODS ANDEntities:
Year: 2020 PMID: 32634861 PMCID: PMC7589246 DOI: 10.1111/dme.14364
Source DB: PubMed Journal: Diabet Med ISSN: 0742-3071 Impact factor: 4.359
Clinical characteristics of type 2 diabetes participants with or without diabetic kidney disease
| Variable | Diabetes‐only group ( | DKD group ( |
|
|---|---|---|---|
| Age at study, years | 60.6 ± 9.4 | 58.9 ± 10.5 | 0.094 |
| Men, | 110 (55) | 129 (62) | 0.150 |
| Diabetes duration, years | 14.7±4.8 | 14.1±5.6 | 0.540 |
| BMI, kg/m2 | 23.7±3.2 | 24.3±2.6 | 0.075 |
| Family history, | 89 (47) | 66 (35) | 0.016 |
| Cigarette history, | 59 (31) | 69 (34) | 0.512 |
| Alcohol history, | 35 (18) | 43 (21) | 0.462 |
| Fasting glucose, mmol/l | 7.7 ± 2.6 | 8.5 ± 4.2 | 0.356 |
| HbA1c | <0.001 | ||
| mmol/mol | 67 ± 19 | 63 ± 25 | |
| % | 8.3±1.7 | 7.9 ± 2.3 | |
| Total cholesterol, mmol/l | 4.4±1.0 | 4.5±1.4 | 0.726 |
| HDL cholesterol, mmol/l | 1.1±0.3 | 1.1±0.4 | 0.396 |
| LDL cholesterol, mmol/l | 2.7±0.9 | 2.8±1.1 | 0.313 |
| Triglycerides, mmol/l | 1.6±1.0 | 1.7±1.0 | 0.438 |
| Haemoglobin, g/l | 133±15 | 104±24 | <0.001 |
| Albumin, g/l | 39.2±3.6 | 31.2±6.1 | <0.001 |
| Uric acid, μmol/l | 287±74 | 335±101 | <0.001 |
| Blood urea nitrogen, mmol/l | 5.7±1.6 | 13.0±8.2 | <0.001 |
| Serum creatinine, μmol/l | 60±18 | 325±304 | <0.001 |
| Urinary albumin level, | <0.001 | ||
| Normal | 185 (95) | 0 (0.0) | |
| Microalbuminuria | 9 (4.6) | 51 (32) | |
| Macroalbuminuria | 0 (0.0) | 107 (68) | |
| Hypertension, | 82 (41) | 166 (80) | <0.001 |
| Diabetic Retinopathy, | 29 (15) | 132 (67) | <0.001 |
| Diabetic Neuropathy, | 96 (48) | 133 (67) | <0.001 |
| Macrovascular complications, | 107 (54) | 122 (60) | 0.222 |
| Diabetic foot, | 9 (4.5) | 25 (13) | 0.0039 |
DKD, diabetic kidney disease.
Data are presented as the mean ± sd (quantitative characteristics), unless otherwise indicated. In statistical comparisons, Student's t‐test or a rank‐sum test was performed for quantitative characteristics, and a chi‐squared test was used for qualitative characteristics.
P < 0.05.
Comparisons of genotype constituent ratios and allele distributions of 16 eligible SNPs between participants with type 2 diabetes with and without diabetic kidney disease
|
Diabetes‐only group
|
DKD group
|
| Adjusted | |
|---|---|---|---|---|
| rs1063537 | ||||
|
| 105 (53) | 112 (54) | 0.691 | |
|
| 84 (42) | 81 (39) | ||
|
| 11 (5.5) | 15 (7.2) | ||
|
| 294 (74) | 305 (73) | 0.953 | |
|
| 106 (27) | 111 (27) | ||
| rs10795433 | ||||
|
| 82 (41) | 66 (32) | 0.136 | |
|
| 86 (43) | 107 (51) | ||
|
| 32 (16) | 35 (17) | ||
|
| 250 (63) | 239 (57) | 0.141 | |
|
| 150 (38) | 177 (43) | ||
| rs10951509 | ||||
|
| 16 (8.0) | 25 (12) | 0.059 | |
|
| 64 (32) | 82 (39) | ||
|
| 120 (60) | 101 (49) | ||
|
| 96 (24) | 304 (52) | 0.014 | 0.224 |
|
| 304 (76) | 284 (48) | ||
| rs11643718 | ||||
|
| 162 (81) | 187 (90) | 0.014 | 0.224 |
|
| 37 (19) | 20 (10) | ||
|
| 1 (0.5) | 1 (0.5) | ||
|
| 361 (90) | 394 (95) | 0.015 | 0.240 |
|
| 39 (10) | 22 (5.0) | ||
| rs1345365 | ||||
|
| 18 (9.0) | 28 (13) | 0.086 | |
|
| 64 (32) | 79 (38) | ||
|
| 118 (59) | 101 (49) | ||
|
| 100 (25) | 135 (32) | 0.019 | 0.304 |
|
| 300 (75) | 281 (68) | ||
| rs1617640 | ||||
|
| 7 (3.5) | 12 (5.8) | 0.554 | |
|
| 65 (33) | 66 (32) | ||
|
| 128 (64) | 130 (63) | ||
|
| 79 (20) | 90 (22) | 0.507 | |
|
| 321 (80) | 326 (78) | ||
| rs1801133 | ||||
|
| 88 (44) | 82 (39) | 0.488 | |
|
| 89 (45) | 95 (46) | ||
|
| 23 (12) | 31 (15) | ||
|
| 265 (66) | 259 (62) | 0.235 | |
|
| 135 (34) | 157 (38) | ||
| rs1917760 | ||||
|
| 130 (65) | 137 (66) | 0.775 | |
|
| 65 (33) | 68 (33) | ||
|
| 5 (2.5) | 3 (1.4) | ||
|
| 325 (81) | 342 (82) | 0.722 | |
|
| 75 (19) | 74 (18) | ||
| rs2237897 | ||||
|
| 97 (49) | 123 (59) | 0.084 | |
|
| 89 (45) | 71 (34) | ||
|
| 14 (7.0) | 14 (6.7) | ||
|
| 283 (71) | 317 (76) | 0.078 | |
|
| 117 (29) | 99 (24) | ||
| rs2241766 | ||||
|
| 105 (53) | 112 (54) | 0.897 | |
|
| 82 (41) | 81 (39) | ||
|
| 13 (6.5) | 15 (7.2) | ||
|
| 292 (73) | 305 (73) | 0.919 | |
|
| 108 (27) | 111 (26) | ||
| rs2268388 | ||||
|
| 122 (61) | 108 (52) | 0.109 | |
|
| 60 (30) | 83 (40) | ||
|
| 18 (9.0) | 17 (8.2) | ||
|
| 304 (76) | 299 (72) | 0.180 | |
|
| 96 (24) | 117 (28) | ||
| rs2283228 | ||||
|
| 93 (47) | 109 (52) | 0.445 | |
|
| 89 (45) | 80 (38) | ||
|
| 18 (9.0) | 19 (9.1) | ||
|
| 275 (69) | 298 (72) | 0.368 | |
|
| 125 (31) | 118 (28) | ||
| rs429358 | ||||
|
| 156 (78) | 173 (83) | 0.387 | |
|
| 43 (22) | 34 (16) | ||
|
| 1 (0.5) | 1 (0.5) | ||
|
| 355 (89) | 380 (91) | 0.215 | |
|
| 45 (11) | 36 (9.0) | ||
| rs4892247 | ||||
|
| 7 (3.5) | 4 (1.9) | 0.252 | |
|
| 56 (28) | 72 (35) | ||
|
| 137 (69) | 132 (63) | ||
|
| 70 (18) | 80 (19) | 0.523 | |
|
| 330 (83) | 336 (81) | ||
| rs7412 | ||||
|
| 166 (83) | 173 (83) | 0.476 | |
|
| 33 (17) | 31 (15) | ||
|
| 1 (0.5) | 4 (1.9) | ||
|
| 365 (91) | 377 (91) | 0.756 | |
|
| 35 (9.0) | 39 (9.0) | ||
| rs741301 | ||||
|
| 18 (9.0) | 23 (11) | 0.706 | |
|
| 91 (46) | 97 (47) | ||
|
| 91 (46) | 88 (42) | ||
|
| 127 (32) | 143 (34) | 0.426 | |
|
| 273 (68) | 273 (66) |
DKD, diabetic kidney disease.
Chi‐squared tests were used for the comparisons of genotype constituent ratios and allele distributions between groups. Bonferroni correction was used for multiple testing correction.
P < 0.05. † P value after multiple testing correction.
Comparisons of genotype and allele of three critical SNPs between participants with type 2 diabetes with and without diabetic kidney disease
| Genotypes (%) | Alleles | OR (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| rs11643718 |
|
|
|
|
|
|
|
| Diabetes‐only | 38 (19) | 162 (81) | 0.10 | 0.90 | 1.935 (1.126, 3.326) | 2.089 (1.178, 3.704) | 2.056 (1.120, 3.776) |
| DKD | 21 (10) | 187 (90) | 0.05 | 0.95 |
|
|
|
| rs10951509 |
|
|
|
|
|
|
|
| Diabetes‐only | 120 (60) | 80 (40) | 0.76 | 0.24 | 1.472 (1.081, 2.004) | 1.589 (1.073, 2.353) | 1.738 (1.143, 2.643) |
| DKD | 101 (49) | 107 (51) | 0.68 | 0.32 |
|
|
|
| rs1345365 |
|
|
|
|
|
|
|
| Diabetes‐only | 118 (59) | 82 (41) | 0.75 | 0.25 | 1.441 (1.062, 1.956) | 1.525 (1.031, 2.255) | 1.681 (1.106, 2.555) |
| DKD | 101 (49) | 107 (51) | 0.675 | 0.325 |
|
|
|
DKD, diabetic kidney disease.
Chi‐squared tests were used for the comparisons of frequencies of studied allele and genotype between diabetes‐only and DKD groups.
Recessive model studied.
Dominant model studied.
Adjusted for age, gender, BMI, diabetes duration, family history and HbA1c.
Figure 1Forest plots of the association between the SLC12A3 rs11643718 polymorphism and diabetic kidney disease (DKD) in people with type 2 diabetes. (a) Forest plot of genotypes in SLC12A3 rs11643718 in the recessive model. (b) Forest plot of alleles in SLC12A3 rs11643718 in the allele model. The position and area of the squares receptively reflect the odds ratio (OR) and weight of each study. The horizontal lines represent the 95% CI of the specific study. The diamond represents the overall OR and 95% CI. P values < 0.05 were considered statistically significant.
Comparisons of renal‐related traits between different genotypes of SLC12A3 rs11643718e
| Variable |
|
|
|
|---|---|---|---|
| Uric acid, μmol/l | 306±87 | 313±93 | 0.607 |
| Abnormal blood urea nitrogen, | 19 (32) | 163 (47) | 0.038 |
| Abnormal Serum creatinine, | 12 (20) | 111 (32) | 0.076 |
| Urinary albumin level, | 0.0052 | ||
| Normal | 36 (69) | 149 (50) | |
| Microalbuminuria | 10 (19) | 50 (17) | |
| Macroalbuminuria | 6 (12) | 101 (34) |
Data are presented as mean ± sd (quantitative characteristics) unless otherwise indicated.
Student's t‐test or the rank‐sum test was performed for quantitative variables, and chi‐squared test for qualitative variables.
P < 0.05.
Figure 2Nephroseq database‐based analyses of the expression of SLC12A3 in human renal tissue. (a) The tissue distribution of SLC12A3 expression in normal human renal tissue. (b) Distribution difference of SLC12A3 between renal tubulointerstitial and glomerulus. (c) The difference in tubulointerstitial SLC12A3 expression between participants with diabetic kidney disease (DKD) and healthy controls (HC). (d) Tubulointerstitial SLC12A3 expression was positively correlated with the estimated GFR (eGFR) in DKD populations. P values for (b) and (c) were obtained by Student’s t‐test; P values for (d) were obtained by Spearman’s correlation analyses. P values < 0.05 were taken to indicate statistical significance.
Figure 3The expression level of SLC12A3 in renal tubules was decreased in participants with type 2 diabetes and diabetic kidney disease (DKD), especially those with the GG genotype in rs11643718. (a) Immunohistochemistry staining of renal biopsy tissues with SLC12A3 antibody in participants with glomerular minor lesions, participants with type 2 diabetes, DKD and the AA+AG genotype in rs11643718, and participants with type 2 diabetes, DKD and the GG genotype in rs11643718. Control, n = 8; DKD with the AA+AG genotype in rs11643718, n = 5; DKD with the GG genotype in rs11643718, n = 8. Bar = 100 μm. (b) The difference in renal tubule SLC12A3 abundance between groups. Values are presented as mean ± sd. The P value was obtained by the Tukey honestly significant difference test. P values < 0.05 were taken to indicate statistical significance.